Core Viewpoint - Agilent Technologies reported a revenue of $1.67 billion for Q2 of fiscal year 2025, representing a 6% year-over-year growth, with a net profit of $373 million [1][2]. Revenue Breakdown - The Life Sciences and Diagnostics Group (LDG) generated revenue of $654 million, an 8% increase year-over-year, with a core business growth of 3% and an operating profit margin of 19.7% [4]. - The Agilent CrossLab Group (ACG) achieved revenue of $713 million, a 7% increase year-over-year, with a core business growth of 9% and an operating profit margin of 32.4% [4]. - The Applied Markets Group (AMG) reported revenue of $301 million, a 1% decline year-over-year, with core business remaining flat and an operating profit margin of 19.5% [4]. Regional Performance - Revenue in China grew by 10%, with strong performance in Asia, while the Americas saw low single-digit growth and Europe, the Middle East, and Africa experienced mid-single-digit growth [7]. - The CEO noted that all end markets achieved mid to high single-digit growth, except for a slight decline in the academic and government sectors [7]. Impact of Tariff Events - The CFO stated that the revenue for Q2 was not affected by the April tariff events, with an estimated additional tariff exposure of $5 million for the second half of the fiscal year [8][9]. - The company has implemented supply chain adjustments and cost-saving measures to mitigate the impact of tariffs, expecting to fully offset related costs by fiscal year 2026 [9].

Core Viewpoint - A new wave of standard updates will be implemented in June 2025, with 572 national, industry, and local standards covering various sectors, including agriculture, environmental protection, healthcare, cosmetics, petrochemicals, and textiles, aimed at promoting industrial upgrades and high-quality development [1][2]. Agriculture and Food Sector - 52 new standards will focus on high-standard farmland construction, oil inspection, and feed safety, providing technical support for agricultural production and food safety [4]. - Specific standards include GB/T 33130-2024 for high-standard farmland construction evaluation and GB/T 44965-2024 for the determination of β-carotene acid ethyl ester in feed using high-performance liquid chromatography [4][9]. Environmental Protection Sector - 18 new standards will address hazardous chemical monitoring, water resource management, and waste treatment, promoting environmental safety and resource efficiency [5][11]. Healthcare Sector - 50 new standards will cover medical devices, forensic identification, and drug testing, enhancing the scientific basis for judicial identification [5][11]. - Notable standards include GB/T 19267.13-2025 for the physicochemical testing of trace evidence in forensic science [5][12]. Cosmetics Sector - 23 new standards will focus on ingredient testing and microbial risk assessment, ensuring consumer health protection [5][11]. - Examples include SN/T 2291-2024 for the determination of dextromethorphan hydrobromide in imported cosmetics using liquid chromatography [5][13]. Petrochemical and Textile Sectors - The petrochemical sector will see 47 new standards, while the textile sector will have 40 new standards, focusing on chemical equipment safety, recycled plastics, and harmful substance testing in textiles [5][11]. - Key standards include GB/T 44958-2024 for chemical equipment safety management and GB/T 31126.2-2024 for the determination of perfluoro and polyfluoro compounds in textiles [5][14]. Overall Impact - The implementation of these new standards is expected to enhance the technical level and management capabilities across industries, driving industrial upgrades and sustainable development while providing consumers with safer, higher-quality products and services [6][11].

Core Viewpoint - The article emphasizes the importance of resource management strategies in enhancing organizational resilience and innovation capabilities for small and medium-sized enterprises (SMEs) in the scientific instrument manufacturing sector in dynamic environments [1][5]. Group 1: Research Objectives - The research aims to explore the internal relationship between resource management strategies and organizational resilience and innovation capabilities in SMEs [1]. - The study invites decision-makers from the scientific instrument R&D manufacturing sector to participate in a survey to share their management experiences [1][3]. Group 2: Survey Details - The survey consists of three main parts: company background information (business type, industry category, size), current organizational resilience and innovation status, and the previous year's environmental dynamics and information management conditions [3]. - The estimated completion time for the survey is approximately 10 minutes [3]. Group 3: Privacy and Participation - The data collected from the survey will be used strictly for academic research and will adhere to confidentiality principles, ensuring no sensitive company or personal information is involved [4]. - Participants can engage in the survey by scanning a QR code or clicking a link provided at the end of the article, with the survey open until June 14, 2025 [5].

Core Viewpoint - Bio-Rad is implementing a tariff surcharge due to the impact of the global trade environment on its manufacturing, particularly affecting its life sciences business, while its diagnostics business remains less impacted due to long-term contracts with clients [1][3][4]. Group 1: Company Strategy and Financial Performance - Bio-Rad's CEO and CFO discussed the company's operational strategies and future outlook at the RBC Capital Markets Global Healthcare Conference, emphasizing their commitment to steady growth through operational improvements and strategic acquisitions despite market challenges [2]. - The company is facing revenue pressure estimated at $40 million, primarily due to reduced research spending and challenges in the Chinese market, particularly affecting clients reliant on NIH funding [4]. - Bio-Rad plans to utilize cash and debt flexibly for acquisitions, focusing on products that align with its existing portfolio to enhance market competitiveness [4]. Group 2: Market Conditions and Future Outlook - The company anticipates continued market weakness from Q2 to Q4, affecting academia, biotechnology, and the Chinese market, although consumable usage remains stable, indicating ongoing laboratory activities [5]. - The negative impact of tariffs is estimated to be around 30 basis points, amounting to $30 million to $40 million, which has already been factored into the company's financial guidance [5]. - Based on historical seasonal trends, Bio-Rad expects that the second half of the year will account for 52% of its annual revenue, with a potential performance rebound anticipated in that period [5].

Core Viewpoint - The Ministry of Industry and Information Technology has announced the preliminary list of the first batch of key cultivation pilot platforms, with a total of 242 platforms selected nationwide, covering essential fields for high-quality development in manufacturing [1][3]. Summary by Relevant Sections Pilot Platforms Overview - A total of 242 pilot platforms have been selected, categorized as follows: 79 in raw materials industry, 62 in consumer goods industry, 60 in equipment manufacturing, 21 in information technology, 13 in emerging and future industries, and 7 in common demand fields [3]. Equipment Manufacturing Sector - In the equipment manufacturing sector, 8 instrument and meter pilot platforms have been included, such as: - China Sensor Valley Intelligent Sensor Pilot Platform - Automotive Sensor Pilot Platform - Instrument Functional Materials and Special Sensors Pilot Platform - High-Precision Grating Scale Manufacturing and Application Pilot Platform - Nuclear Power Plant Instrument Pilot Platform - Beijing Jingyi High-End Instruments and Meters Pilot Platform - Guangdong Precision Instruments Advanced Manufacturing Technology Pilot Platform - Mechanical Industry Instrument Comprehensive Research Institute MEMS Sensor Pilot Platform [3][4]. Consumer Goods Industry - In the consumer goods industry, 33 pharmaceutical pilot platforms have been selected, including: - Liaoning Shangyao Northern Pharmaceutical Chemical Pilot Platform - Gene Engineering Drug Clinical Test Sample Preparation Pilot Platform - Innovative Drug Pilot Platform - Various medical device pilot platforms such as the West Lake IBT Biological Intelligence Pilot Platform and Regenerative Medicine Technology and Material Transformation Pilot Platform [5][6]. Medical Devices Sector - The medical devices sector includes 7 pilot platforms, such as: - West Lake IBT Biological Intelligence Pilot Platform - Medical Device Preclinical Animal Testing Safety Efficacy Verification and Inspection Testing Pilot Platform - Blood Dialysis Machine Pilot Platform - Beijing High-End Medical Device CDMO Pilot Platform - Regenerative Medicine Technology and Material Transformation Pilot Platform [7][8].

导读： 近日，中国海洋大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出18项仪器设备采购意向， 预算总额达1.19亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 中国海洋大学发布 18 项仪器设备采购意向，预算总额达 1. 19 亿 元，涉及水层化海洋模拟实验系统 、 水下 PIV测量系统 、表面波生成与测量一体化系统、海床基在线观测系统 等，预计采购时间为202 5 年 5 月。 中国海洋大学2025年5月 仪器设备采购 意向汇总表 | | | 采 | | --- | --- | --- | | 采购 | | 预算 购 | | | 需求概况 | | | 项目 | | 万元 时 | | 冰洋水 | | 间 | | 文-光 | | 202 | | 学-生 | 本项目建设包括深远海立体观测体系以及学科物理模拟实验平台。包含冰洋水文-光学-生态观测链6台套，自容温盐深观测链3台套，海 | 5 | | 态观测 | 洋大尺度热力动力模拟系统1台套，帮助学生理解海洋大尺度热力和动力过程；提升对北冰洋中小尺度过程 ...

Core Viewpoint - Agilent has launched the InfinityLab Pro iQ series of liquid chromatography-mass spectrometry (LC-MS) systems, which includes Pro iQ and Pro iQ Plus, designed to enhance efficiency and accuracy in molecular analysis [2][3]. Group 1: Product Overview - The Pro iQ series caters to diverse analytical needs in pharmaceutical and biopharmaceutical R&D, chemical and specialty materials manufacturing, as well as academic and government research [3]. - The systems are equipped to support applications such as quality assurance, impurity analysis, biomolecular characterization, trace contaminant detection, and compound purification, providing reliable results for both routine and advanced workflows [3]. Group 2: Technical Features - Pro iQ Plus is designed for high-sensitivity and high-performance applications, with a mass range extending to m/z 2–3000, utilizing Agilent's Jet Stream Ion Source technology to enhance sensitivity [4]. - The Pro iQ system has a mass range of m/z 2–1600, optimized for small molecule analysis, making it a reliable choice for routine laboratory workflows [6]. Group 3: Market Impact - The introduction of the Pro iQ series signifies Agilent's commitment to redefining the future of liquid chromatography detection, enabling researchers to obtain high-value information and improve efficiency in complex analyses [3]. - The multifunctionality of the Pro iQ series opens new opportunities in pharmaceutical development, quality control, biotherapeutics, environmental testing, and academic research [3].

Core Viewpoint - Agilent Technologies has appointed August Specht as the Chief Technology Officer, bringing over 25 years of experience in the design, development, and marketing of analytical instruments, software, and consumables [1]. Group 1: Appointment Details - August Specht previously served as the Vice President of Global R&D for the Chromatography and Mass Spectrometry Division at Thermo Fisher Scientific [1]. - Specht will join Agilent on June 9 [1]. - Agilent's President and CEO, Padraig McDonnell, expressed enthusiasm about Specht's appointment, highlighting his deep understanding of the evolving needs of the scientific community [1]. Group 2: Educational Background - August Specht holds a Bachelor’s degree in Chemistry (Honors) from Queen's University, a PhD in Analytical Chemistry from the University of British Columbia, and an MBA from the University of California, Berkeley [2].

Core Viewpoint - The National Pharmacopoeia Commission has released a draft for the standard of the 1001 Polymerase Chain Reaction (PCR) method, which includes the addition of real-time quantitative PCR and revisions to conventional PCR methods [1][2]. Summary by Sections Introduction - The draft standard introduces new methods for quantitative detection using PCR, specifically adding real-time fluorescence quantitative PCR as a second method. It covers general requirements for instruments and reagents, measurement methods, and method validation requirements [2][6]. Revisions to Conventional PCR Method - The conventional PCR method has been revised to include: 1. Quality requirements for template DNA extraction from traditional Chinese medicine and biochemical drugs, including OD260/OD280 ratios for nucleic acid quality control. 2. Requirements for method applicability, including sequence, annealing temperature, types of restriction endonucleases, DNA polymerase concentration, and enzyme digestion time. 3. The addition of DNA characteristic sequences as quality control DNA markers [7][14]. Real-time Fluorescence Quantitative PCR Method - The real-time quantitative PCR method is designed for real-time detection of PCR amplification products, allowing for quantitative analysis of starting templates. It is applicable for specific nucleic acid components in traditional Chinese medicine, raw materials, intermediates, active pharmaceutical ingredients, and excipients [25][26]. - General requirements for instruments include continuous temperature control and the ability to excite and read fluorescence signals in real-time [25][26]. Method Validation Requirements - New methods must undergo validation, which includes defining experimental plans, analysis steps, and acceptable standards. Validation indicators are closely related to the intended use of the method, such as specificity for qualitative identification and accuracy, precision, linearity, and range for quantitative detection [29][30]. Laboratory Requirements - Laboratories must meet national biosafety management requirements and implement measures to prevent cross-contamination, such as functional area separation and pressure control [30].

导读： 近日，中国科学技术大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出30项仪器设备采购意 向，预算总额达9432万元。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号立 场 | 采购 | 需求 | 预算 | 采购 | | --- | --- | --- | --- | | 项目 | 概况 | 万元 | 时间 | | 储存环 | | | | | 数字 | 计划用于合肥先进光源工程建设储存环束测系统束流位置测量子系 | | 2025 | | BPM | 统，共需 242套数字BPM处理器。 | 2582 | 年6 | | 处理器 | | | 月 | | BPM | 计划用于合肥先进光源工程建设注入器与储存环束测系统束流位置 | | 2025 | | | 测量子系统，共需 LMR400电缆约82千米，衰减约为 | 112 | 年7 | | 主电缆 | 9dB/100m@500MHz，外径10.29mm。 | | 月 | | | 实现 BPM探头信号的和差信号计算，4进4出，20MH ...